FDA rejects Adamis opioid overdose therapy Zimhi, hitting share priceShares in Adamis Pharmaceuticals have been poleaxed by an FDA decision to reject Zimhi, intended as a treatment Share XFDA rejects Adamis opioid overdose therapy Zimhi, hitting share pricehttps://pharmaphorum.com/news/fda-rejects-adamis-opioid-overdose-therapy-zimhi-hitting-share-price/
FDA approves Adamis’ cheaper rival to EpiPenSymjepi also smaller and more convenient. Share XFDA approves Adamis’ cheaper rival to EpiPenhttps://pharmaphorum.com/news/adamis-mylan-epipen/